The Growth of Seattle Genetics & The Role of Dr. Clay Siegall

Cancer seems to be as prevalent now as it has ever been in the past. This deadly disease just seem to be any and everywhere around the globe. There has been some major changes over the past decade thanks to the production of some of the most innovative medications in cancer research has come to light. Antibody Based Therapies are the name and saving lives is the game. One of the top cancer fighting organizations in the world is Seattle Genetics and it has become a powerhouse in the history since it’s birth back in the late 90’s. This exclusive organization produces and distributes some of the most advanced antibody drug conjugates of this business. These powerful therapies attack cancerous cells with cell killing agents which eradicates them.

 

The head guy in charge at the Bothell, Washington based company is Dr. Clay Siegall and he has played an intricate role in the fight against cancer throughout the years. This guy is the real deal when it comes to getting things done. Dr. Siegall has an extensive educational background as he holds a (BS) in Zoology from The University of Maryland and a Ph.D from George Washington University. Besides being the President and CEO of the organization, he also one of it’s founders. Dr. Siegall has taken the industry by storm as of late as Seattle Genetics will be going through much bigger changes such as hiring another 200 employees, release about five new drugs in the near future, and expanding their services instead of remaining a single drug company. Big things are on the horizon and most of these changes are coming from Dr. Siegall.

 

The company’s social media presence is ever growing as well. There are thousands of followers whom keep track of the company’s every move. Many of Seattle Genetics’ events, photos, and updates can be found here also which keeps everyone in “the know.” Overall the future of cancer research is constantly changing with ups and downs, but the positives definitely outweigh the negatives.

Leave a Reply